



PULMONARY SURFACTANT THERAPIES: FROM THE BIOPHYSICS LABORATORY TO NEW DEVELOPMENTS IN RESPIRATORY MEDICINE

DEL 3 AL 5 DE JULIO

CÓDIGO: 72301

Director: Jesús Pérez Gil. Universidad Complutense

Secretaria: Mercedes Echaide Torreguitar. Universidad Complutense

Cordinador: Eduardo Martínez Naves

Patrocina: Chiesi Farmaceutici S.p.A.; Fundación Lovexair; Asociación de Familiares y Enfermos de Fibrosis Pulmonar idiopática

Colabora: Instituto de Investigación Hospital 12 de Octubre; Centro de Investigación Biomédica en Red – Enfermedades respiratorias



AFEFPI
Asociación de Familiares y Enfermos
de Fibrosis Pulmonar Idiopática



ciberes isciü

The pulmonary surfactant system, rather unknown by the general public, is however an essential element to facilitate the mechanical work of lungs, in charge of mobilizing the thousands of liters of air required for providing the oxygen that the tissues need to be alive. The absence or deficiency of surfactant lead to severe respiratory pathologies, some of which are routinely treated at the intensive care units of our hospitals. During the last decades, the exogenous surfactant supplementation therapies have saved thousands of baby lives. Other important pathologies, like pulmonary fibrosis, are still one of the major causes of mortality at the intensive care units of our hospitals. Much research is still needed to develop new surfactant materials good enough to treat severe paediatric and adult pathologies. Much has also to be done to develop efficient treatments for rare respiratory diseases.

This course will review the current situation of the basic research in this field as well as the future transfer of this knowledge to the clinics.



PULMONARY SURFACTANT THERAPIES: FROM THE BIOPHYSICS LABORATORY TO NEW DEVELOPMENTS IN RESPIRATORY MEDICINE

DEL 3 AL 5 DE JULIO

Lunes, 3 de julio

- 10.30 h. Jesús Pérez Gil.** Universidad Complutense
Opening: Basic research in pulmonary surfactant, still something to be discovered?
- 11.30 h. María Carmen Rey-Santano.** Researcher at Instituto de Investigación BioCruces, Bilbao
Animal models of pulmonary surfactant-related pathologies
- 12.30 h. Klaus-Michael Lehr.** Professor at Saarland University
Towards novel pulmonary surfactant-based nanomedicines
- 16.00 h. Round Table:** Pulmonary surfactant, from lab to clinics
Chair: **Jesús Pérez Gil**; Participate: **Klaus-Michael Lehr**; **Manuel Sánchez Luna**. Chief of Neonatology Service, Hospital Gregorio Marañón; **Cristina Casals**. Universidad Complutense; **Federico Bianco**. Neonatology Project Leader, Corporate Drug Development, Chiesi R&D

Martes, 4 de julio

- 10.00 h. Elena Lopez-Rodriguez.** Researcher at Hannover University
Molecular, cellular and animal models of lung fibrosis
- 12.00 h. Matthias Griese.** Coordinator of European Management Platform for Childhood Interstitial Lung Diseases
Congenital pulmonary diseases
- 16.00 h. Round Table:** Research, drug development and therapies targeting rare lung diseases
Chair: **Jesús Pérez Gil**; Participate: **Elena Lopez-Rodriguez**; **Matthias Griese**; **Julio Ancochea**. Chief of Neumology Service, Hospital de La Princesa; **Shane Fitch**. CEO Lovexair Foundation; **Carlos Lines**. President of Asociación de familiares y enfermos de fibrosis pulmonar idiopática



Miércoles, 5 de julio

- 10.00 h. Daniele De Luca.** Chief of Service Neonatology and Neonatal Intensive Care Unit, South Paris University Hospitals, "A.Beclere" Medical Center; Secretary European Society of Pediatrics and Neonatal Intensive Care
Pulmonary surfactant at NICU. Twenty years saving babies lives
- 11.00 h. Manuel Sánchez-Luna.** President of European Union of Neonatology and Perinatal Medicine Societies
Traslational research and neonatal critical care.
- 12.00 h.** Clausura y entrega de diplomas

*Este curso se impartirá en inglés